The Bacillus Subtilis Market size is anticipated to grow at a CAGR of 3.6%, from USD 6.21 Bn in 2026 to approximately USD 7.94 Bn by 2033. The market growth is mainly attributed to the increased use of Bacillus subtilis in animal feed and probiotics preparations, growing need for biological plant protection and soil enhancement solutions, growing use of the bacteria in food processing and health supplements, and the increasing use of the bacteria in pharmaceuticals and industrial biotechnology applications. The stability, ability to form spores, adaptability to the environment, and production of enzymes and antimicrobials facilitate the commercial application of the bacteria in the mentioned industries. According to the 2025 Alltech Agri-Food Outlook, global feed production increased by 1.2%, from 1.380 Bn metric tons in 2023 to 1.396 Bn metric tons in 2024.
The transition from conventional chemical pesticides toward biological crop-protection products is increasing demand for Bacillus subtilis-based formulations. The microorganism can suppress plant pathogens through antimicrobial metabolite production, competition for nutrients and colonization sites, and stimulation of plant-defense mechanisms. Its spore-forming ability also supports longer shelf life and greater environmental stability in commercial microbial pesticides.
The U.S. Environmental Protection Agency’s updated biopesticide database includes several Bacillus subtilis strains used as biological active ingredients. The EPA filed for the initial registration of the strain Bacillus subtilis CH4000 in 2024. In the November 2024 Biocontrol News Update released by the EPA, it was indicated that microbial pesticides tend to be quickly degraded and may be effective in small quantities. They also offer additional tools in integrated pest management programs.
In May 2026, it was determined that Bacillus subtilis M10 decreased common-bean root-rot by 20-28%, reduced the level of wilting by 20-37%, and boosted grain yield by more than 56-75%. These facts show how the organism can be used for both plant protection and improvement of its productivity.
Increasing application of spore-forming probiotics in food and beverage industry is driving the growth of Bacillus Subtilis Market. In contrast to many other probiotic bacteria, spores of bacillus subtilis are able to withstand heat, variations in moisture levels, acidic environment, and long-term storage.
In January 2024, the U.S. Food and Drug Administration completed its review of GRAS Notice No. 1143 for Bacillus subtilis NRRL 68053 and issued a “no questions” response. The strain is suggested for use in regular foods as an ingredient at an upper limit of 1 × 10¹⁰ CFU per unit serving. The result of regulation offers a clear path towards the inclusion of high concentration Bacillus subtilis strains in consumer foods.
|
Current Event |
Description and its Impact |
|
European Commission Expands Bacillus Subtilis Feed-Additive Authorization to All Animal Species (2025) |
|
|
EU Authorizes Bacillus Subtilis-Based Feed Additive for Laying and Breeding Poultry (2025) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
On the basis of product type, the 100–300 Billion CFU/g segment is projected to account for the largest Bacillus Subtilis Market share of approximately 60.0% in 2026. The segment’s growth is owing to its balance of high microbial concentration, lower dosage volume, formulation flexibility, storage stability, and suitability for feed additives, probiotic foods, pharmaceutical formulations, agricultural biologicals, and industrial microbial products.
The Australian Therapeutic Goods Administration’s compositional guideline for Bacillus subtilis strain NRRL B-67989 specifies that the ingredient is dried to a concentration of 100–200 billion CFU/g, directly positioning the regulated ingredient within the leading concentration category. The guideline also establishes 100–200 billion CFU/g as the acceptable total viable-cell-count specification for the strain.
In May 2026, Taiwan-based Ming Chyi Biotechnology Ltd. showcased its MASTERBiotics MBS2000 probiotic ingredient through the official FOOD TAIPEI 2026 product platform. MBS2000 contains Bacillus subtilis at a concentration of up to 200 billion CFU/g, placing it directly within the 100–300 Billion CFU/g segment.

To learn more about this report, Request Free Sample
On the basis of application, the feed additive segment is projected to lead the Bacillus Subtilis Market with approximately 29.0% share in 2026. The segment’s growth is owing to the increasing use of heat-resistant Bacillus subtilis spores in poultry, livestock, and aquaculture feed to support intestinal microbial balance, nutrient digestion, feed utilization, animal productivity, and resistance to adverse production conditions.
A February 2026 evaluation report from the European Union Reference Laboratory assessed an authorization application for Bacillus subtilis DSM 34755 as a feed additive for all aquatic species. The proposed additive contains at least 1 × 10⁹ CFU/g, while its intended minimum inclusion level is 1 × 10⁹ CFU per kilogram of compound feed. The strain is of marine origin and is proposed as a non-genetically modified, spray-dried preparation. This indicates that Bacillus subtilis-based feed applications are expanding beyond conventional poultry and livestock products into aquaculture nutrition.

To learn more about this report, Request Free Sample
Asia-Pacific will hold about 41.5% of the Bacillus Subtilis Market share by 2026 and is estimated at about USD 2.58 Billion. This dominance of the region can be attributed to the strong agricultural and livestock production foundation that the region enjoys, as well as advancements in microbial fermentation and increased usage of bio-inputs for farming purposes.
In November, 2025, the Indian state government of Kerala announced Bacillus subtilis as the State Microbe due to its biosafety attributes and wide range of applications including agriculture, biosurfactants, bioremediation, food fermentation, and even human health applications. Such an official announcement is anticipated to enhance the research on microbiomes, strains, and commercial ventures involving Bacillus subtilis.
The region is also developing Bacillus subtilis for industrial purposes. In December 2025, Food Standards Australia New Zealand approved IFF Australia’s application for the use of dextransucrase produced by Bacillus subtilis for food processing. The enzyme would assist in producing oligosaccharides and polysaccharides, decrease the sucrose levels, and improve food textures.
North America is anticipated to register the fastest growth in the Bacillus Subtilis Market during 2026–2033. The region’s growth is owing to rapid commercialization of microbial agricultural products, strong probiotic-product innovation, advanced fermentation infrastructure, and expanding regulatory pathways for Bacillus subtilis-based food, feed, and crop-protection applications.
Commercial innovation is also expanding the organism’s use in human-health products. In December 2025, U.S.-based Microbiome Labs announced the launch of DigestMate, which combines 14 digestive enzymes with spore-forming probiotics, including Bacillus subtilis HU58. The product became available through healthcare practitioners in May 2025 and entered broader online distribution in December 2025.
The U.S. Bacillus Subtilis Market is witnessing strong growth owing to the country’s established microbial-pesticide regulatory framework, expanding organic and regenerative agriculture sector, advanced fermentation capabilities, and increasing research into Bacillus subtilis-based crop-protection and industrial biotechnology applications.
As of July 2026, the U.S. Environmental Protection Agency’s database contained 457 registered biochemical and microbial biopesticide active ingredients, including multiple Bacillus-based active ingredients. The existence of a mature regulatory pathway is supporting the development and commercialization of Bacillus subtilis-based biofungicides, seed treatments, soil applications, and foliar crop-protection products.
China is expected to remain a major growth market for Bacillus subtilis owing to its large feed-production industry, substantial livestock and aquaculture sectors, extensive microbial-fermentation capacity, and widening regulatory acceptance of Bacillus subtilis-derived food enzymes and biological products.
China is also widening the industrial food-processing applications of Bacillus subtilis. In February 2026, the National Health Commission approved 11 new food-additive varieties, including D-psicose 3-epimerase sourced from Bacillus subtilis and glucose isomerase produced using Bacillus subtilis 168-N03. These enzymes have applications in specialty sweetener, starch-processing, and carbohydrate-conversion processes.
Some of the major key players in Bacillus Subtilis Market are Bayer AG, BASF SE, Jocanima Corporation, Tonglu Huifeng, Kernel Bio-tech, Wuhan Nature's Favour Bioengineering Co., Ltd., Real IPM, ECOT China, and Qunlin.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 6.21 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.6% | 2033 Value Projection: | USD 7.94 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Bayer AG, BASF SE, Jocanima Corporation, Tonglu Huifeng, Kernel Bio-tech, Wuhan Nature's Favour Bioengineering Co., Ltd., Real IPM, ECOT China, and Qunlin. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients